ANNUAL CONFERENCE DEGUZ.EV 2019

 

Some impressions from the 11th annual DEGUZ.eV 2019!
Dr. Lechner was back with his Orotox booth and also able to present the new CaviTAU® device for the first time.

We would like to thank the congress center and the IMD Berlin for organizing the event.

https://www.facebook.com/PraxisklinikDrLechner/videos/1403352569807917/

AN OVERVIEW OF THE NEWSLETTER OF APRIL

We are pleased to inform you, that we are in the final stages regarding the relaunch phase of the CaviTAU® device.
The device is currently being used in in the practice clinic Dr.Lechner and already exceeds our internal expectations.
In addition, we are currently planning so-called “device / demonstrations” at events. (e.g. the DEGUZ annual meeting or at a later date.
The official launch is planned for the end of summer this year, an official date for the market launch is yet to be announced. Unfortunately, due to the ongoing approval process, we can not yet give any information about the selling price. For a presale right you can register here as an ICOSIM member until 30.06.2019 for free.
All newsletter subscribers will be the first ones to know about the final launch date and launch price.

PUBLICATION OF THE VOLUME III „CAVITY FORMING OSTEOLYSIS OF THE JAWBONE“

After the publication of Volume I in 2011 and Volume II in 2015, Volume III, on the cavity-forming osteolyses of the jawbone with their oral and systemic manis fixations, will be published in 2019 by Dr.Dr.(PhDUCN) J. Lechner, Prof. JE. Bouquot und Dr. V. von Baehr.

with more than 600 colored illustrations and over 1,000 literature citations on more than 800 pages explain and justify the new therapy and research branch of a „Maxillo-Mandibular Osteoimmunology”.

PROMOTION BY AN INITIATIVE OF A BAVARIAN MINISTRY 2018

Promotion of the CaviTAU® project by an initiative of the Bavarian Ministry of Economic Affairs

Our developments on CaviTAU® are funded by the state, as the decision makers of the Bavarian Ministry of Economic Affairs (Bayern-Innovativ) have recognized the importance of our TAU ultrasound equipment in dental diagnostics. The future-oriented significance of the treatment options for autoimmune diseases opened up by CaviTAU® is thereby strengthened.

So far, as a nice recognition, we have been awarded four innovation vouchers for the development of the CavTAU® device and its validation on patients.

WHY IS A DENSITY MEASUREMENT OF THE JAWBONE BY ULTRASOUND NECESSARY FOR HEALTH?

a) FDOJ (fatty-degenerative Osteolysis/Osteonecrosis of the Jawbone) is characterized by the absence of the usual clinical parameters of local tooth and jaw pain, with the exception of the more diffuse atypical facial pain (FDOJ is in these pain cases called “NICO”) and the radiographic inconspicuousness.
(Literatur: Lechner, J. Validation of dental X-ray by cytokine RANTES – comparison of X-ray findings with cytokine overexpression in jawbone. Clinical, Cosmetic and Investigational Dentistry 2014:6 71–79..: https://www.dovepress.com/articles.php?article_id=18049&l=bBexMykzNGYEHIPfWZ1MT6xu198194

b) FDOJ is morphologically and macroscopically characterized by a fatty-degenerative dissolution of the spongiosal jawbone with conspicuous structural softening and osteolysis.
(Literature: Lechner J, von Baehr V. Chemokine RANTES/CCL5 as an unknown link between wound healing in the jawbone and systemic disease: is prediction and tailored treatments in the horizon? EPMA Journal.2015, 6:10. DOI: 10.1186/s13167-015-0032-4

EPMA Journal 2015, 6:10 (Section: Traditional, Complementary and Alternative Medicine)
https://www.epmajournal.com/content/6/1/10

c) FDOJ shows the typically excessive signaling of the proinflammatory chemokine RANTES / CCL5 in almost all areas examined.
(Literatur: Lechner J, von Baehr V. “RANTES and fibroblast growth factor 2 in jawbone cavitations triggers for systemic disease”.
https://www.dovepress.com/articles.php?article_id=12842&l=bBexMykzNGYEHIPfWZ1MT6xu198194

d) Our research indicates that overactivated signal transduction cascades may be specific to RANTES / CCL5 in radiologically unrecognized FDOJ sites in association with RANTES / CCL5 effects in complex chronic diseases. For the first time, we present a scientifically validated explanatory model of the so-called “disturbance field effect” from jawbone area.
(Literature: Lechner J, von Baehr V. Journal of Breast Cancer: Basic and Clinical Research: „Hyperactivated Signaling Pathways of Chemokine RANTES/CCL5 in Osteopathies of Jawbone in Breast Cancer Patients—Case Report and Research”.

Free download: https://la-press.com/article.php?article_id=4214. )

However, in a literature review, the modern knowledge gained on the pathophysiological role of the chemokine RANTES / CCL5 in systemic diseases contrasts with minimal hits in relation to RANTES / CCL5 from FDOK areas: Are keywords in the search engine GoogleScholar for 22 diseases and their connection to RANTES / CCL5 “Allergy AND RANTES CCL5” hits 9,500, “Cancer Reviews AND RANTES CCL5” 9,410, “Rheumatoid Arthritis AND RANTES CCL5” 7,310, “Colon Cancer” 6,330, ” Breast Cancer, etc. “to 5,150,” Multiple Sclerosis, etc. “to 5,140,” Pancreas Carcinoma, etc. “to 4,180,” Melanoma, etc. “to 3,940,” Breast Cancer Metastasis, etc. “to 3,750,” Prostate Cancer, etc. “at 3,480,” Depression, etc. “at 2,440,” Alzheimer Disease, etc. “at 2,190,” Thyroid, etc. “at 1,940,” Thyroid, etc. “at 1,940,” Hodgkin, etc. ” “Au f 1,770, “Non-Hodgkin, etc.” to 1,750, “Parkinson’s Disease, etc.” to 1,370, “Periodontitis, etc.” to 942, “Opioid Receptor, etc.” to 862, “ALS, etc.” on 556, on “Lichen Planus, etc.” on 356, on “Trigeminal Neuralgia, etc.” on 227, on “Jawbone, etc.” on 32, of which 14 are their own publications.

Conclusion: RANTES / CCL5 is obviously at the center of interest in numerous scientific publications and at the same time in numerous organ systems in the center of pathogenetic processes.
On the one hand, RANTES / CCL5 is addressed as a possible key element in more than 72,000 GoogleScholar publications for the upper mentioned 22 clinical pictures. On the other hand, the extremely low number of RANTES / CCL5 researches on possible FDOJ organ pathology with 32 hits in GS reveals the lack of scientific and clinical interest in cavitational osteolysis in the medullary space of the jawbone. As a noteworthy deficit, these osteopathies are not the subject of scientific investigation in the dental community nor are they related to their involvement in systemic meta-inflammation via immunological RANTES / CCL5 signaling pathways.

This extreme imbalance demonstrates the need for an imaging technique in the form of reproducible and user-independent quantitative ultrasound measurement of the jawbone.

We face this challenge with the development of the modern CaviTAU® device.

CAVITAU MEASUREMENT JANUARY 2017

Enoral measurement of bone density with the new CaviTAU® device by trans-alveolar ultrasound (TAU)®

We therefore present you this pilot measurement with the CaviTAU® prototype because the measurement results are confirmed clinically: A 34-year-old female patient has been suffering from atypical facial pain for 2 years, starting from the upper left jawbone area in severely repeating pain attacks. After the first “NICO” surgery by removal of the fatty degenerative jawbone (FDOJ) at area 25/26, the neuralgic facial pain disappears completely. Here we compare in several pictures the difference in bone density by means of CaviTAU® imaging of successfully restored FDOJ / “NICO” (area 25 in Figure 1) with jawbone areas still loaded with FDOJ (area 15 in Figure 3) in the same patient.

CaviTAU® ultrasound imaging of an still existing FDOJ in area 15. The direction of the measurement path runs from occlusal to apical or from caudal to cranial:

The interpretation of CaviTAU® imaging in non-rehabilitated jawbone area 15;  the attenuation of the dental plastic bridge at 15 has not yet been fully investigated.

The CaviTAU® imaging at area 25 five months after successful rehabilitation of the trigeminal neuralgia; patient is now completely free of pain. X-ray is preoperative uptake. The direction of the measurement path runs from occlusal to apical or from caudal to cranial.

The interpretation of ultrasound imaging in the restored jawbone in area 25 (no FDOJ/“NICO”).

The significance and clinical need for a TAU analysis in cases of chronic atypical facial pain or trigeminal neuralgia and the inadequate presentation of fatty-degenerative osteolysis in the jawbone FDOJ / “NICO” by X-rays is documented in our own scientific publications:

Lechner J, von Baehr V. Peripheral Neuropathic Facial/Trigeminal Pain and RANTES/CCL5 in Jawbone Cavitation, Evidence-Based Complementary and Alternative Medicine, vol. 2015, Article ID 582520, 9 pages, 2015. doi:10.1155/2015/582520https://www.hindawi.com/journals/ecam/2015/582520/
Lechner, J. Validation of dental X-ray by cytokine RANTES – comparison of X-ray findings with cytokine overexpression in jawbone. Clinical, Cosmetic and Investigational Dentistry 2014:6 71–79https://www.dovepress.com/articles.php?article_id=18049
https://www.ncbi.nlm.nih.gov/pubmed/25170282
All publications by Hans Lechner and co-authors can be found on the Science Platform Researchgate https://www.researchgate.net/profile/Johann_Lechner/publications

 

PROMOTION BY AN INITIATIVE OF A BAVARIAN MINISTRY 2016

Promotion of the CaviTAU® project by an initiative of the Bavarian Ministry of Economic Affairs

Our developments on CaviTAU® are funded by the state, as the decision makers of the Bavarian Ministry of Economic Affairs (Bayern-Innovativ) have recognized the importance of our TAU ultrasound equipment in dental diagnostics. The future-oriented significance of the treatment options for autoimmune diseases opened up by CaviTAU®is thereby strengthened:

PROMOTION BY AN INITIATIVE OF A BAVARIAN MINISTRY 2013

Promotion of the CaviTAU® project by an initiative of the Bavarian Ministry of Economic Affairs

Our developments on CaviTAU® are funded by the state, as the decision makers of the Bavarian Ministry of Economic Affairs (Bayern-Innovativ) have recognized the importance of our TAU ultrasound equipment in dental diagnostics. The future-oriented significance of the treatment options for autoimmune diseases opened up by CaviTAU® is thereby strengthened.